A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the objective response rate of ABT-888 when given
in combination with temozolomide versus pegylated liposomal doxorubicin (PLD) alone in
subjects with recurrent high grade serous ovarian cancer.